Current developments of immunotherapy in the clinic

The clinical application of immunotherapy for cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of ‘therapeutic’ vaccines. Recently, both clinical and immunological endpoints have shown improvement. Novel strategies designe...

Full description

Saved in:
Bibliographic Details
Published inCurrent opinion in immunology Vol. 16; no. 2; pp. 130 - 136
Main Authors Antonia, Scott, Mulé, James J, Weber, Jeffrey S
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.04.2004
Subjects
Antigens, Neoplasm - immunology
Cancer Vaccines - therapeutic use
Clinical Trials as Topic
Dendritic Cells - immunology
Humans
Immunotherapy, Adoptive - methods
Immunotherapy, Adoptive - trends
Melanoma - immunology
Melanoma - therapy
Neoplasms - immunology
Neoplasms - therapy
Recombinant Proteins - immunology
T-Lymphocytes - immunology
PR
IL
Hsp
MART-1
MR
TNF
CR
IFN
MAGE
SD
GM-CSF
CTL
CTLA-4
TLR
HLA
PCR
Online AccessGet full text

Cover

More Information
Summary:The clinical application of immunotherapy for cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of ‘therapeutic’ vaccines. Recently, both clinical and immunological endpoints have shown improvement. Novel strategies designed in the laboratory and proven in preclinical animal tumor models are now entering the clinic, with the intent of enhancing current therapeutic efficacy. These novel strategies involve breaking tolerance to tumor self-antigens by inhibiting regulatory cells, boosting T-cell co-stimulation and using combinations of recombinant cytokines and other defined molecules with ‘immuno-enhancing’ activities.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ObjectType-Feature-3
ObjectType-Review-1
ISSN:0952-7915
1879-0372
DOI:10.1016/j.coi.2004.01.012